Dummer, Reinhard Flaherty, Keith Robert, Caroline Arance, Ana Maria De Groot, Jan Willem Garbe, Claus Gogas, Helen and Gutzmer, Ralf Krajsova, Ivana Liszkay, Gabriella Loquai, Carmen Mandala, Mario Schadendorf, Dirk Yamazaki, Naoya and Pickard, Michael D. Zohren, Fabian Edwards, Michelle L. and Ascierto, Paolo Antonio, Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial
of encorafenib plus binimetinib versus vemurafenib or encorafenib in
patients (pts) with BRAF V600-mutant melanoma., World Journal of Clinical Oncology, (39), 2021, Lippincott, Williams & Wilkins,